ホーム › 大うつ病性障害 › フロリダ州 › Orlando
Orlando、FLにおける大うつ病性障害の臨床試験
Orlandoとその周辺地域（約30マイル以内）の拠点で、大うつ病性障害に関する19件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
被験者募集中第3相
- Nova Psychiatry INC, Orlando
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
被験者募集中第2相
- Clinical Neuroscience Solutions Inc. - Orlando, Orlando
- K2 Medical Research - Maitland, Maitland · 6マイル先
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
被験者募集中第3相
- Accel Research Sites - Maitland, Maitland · 6マイル先
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
被験者募集中第2相
- Seaport Investigator Site, Orlando
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
被験者募集中第2相
- Clinical Neuroscience Solutions, Inc., Orlando
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
被験者募集中第2相
- Draig Clinical Site, Orlando
- Draig Clinical Site, Orlando
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
被験者募集中第2相
- Draig Clinical Site, Orlando
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
被験者募集中第3相
- Clinical Neuroscience Solutions, LLC (Orlando), Orlando
- Charter Research, Orlando
- K2 Medical Research (Maitland), Maitland · 6マイル先
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
被験者募集中第3相
- Neurocrine Clinical Site, Maitland · 6マイル先
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
被験者募集中第3相
- Charter Research - Orlando, Orlando
- K2 Medical Research - Maitland, Maitland · 6マイル先
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
被験者募集中第3相
- Clinical Neuroscience Solutions, Inc., Orlando
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
被験者募集中第2相
- Clinical Neuroscience Solutions, Inc., Orlando
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
被験者募集中第3相
- Neurocrine Clinical Site, Orlando
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
被験者募集中第3相
- Neurocrine Clinical Site, Maitland · 6マイル先
- Neurocrine Clinical Site, Maitland · 6マイル先
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
被験者募集中第2相
- Clinical Neuroscience Solutions - Orlando - East South Street /ID# 277558, Orlando
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
被験者募集中第3相
- Neurocrine Clinical Site, Maitland · 6マイル先
Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics
被験者募集中
- AdventHealth Neuroscience Institute, Orlando
Study of ALTO-300 in MDD
被験者募集中第2相
- Site 159, Clermont · 24マイル先
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
被験者募集中第4相
- Clinical Research Site, Orlando
- Clinical Research Site, Orlando
- Clinical Research Site, Orlando
他の都市における大うつ病性障害の試験
- New York City, NY37件の研究
- Boston, MA31件の研究
- Atlanta, GA25件の研究
- Philadelphia, PA23件の研究
- Miami, FL18件の研究
- Chicago, IL17件の研究
- Tampa, FL17件の研究
- Houston, TX16件の研究
- San Diego, CA16件の研究
- Little Rock, AR14件の研究
- Orange, CA13件の研究
- Austin, TX13件の研究
Orlandoにおける他の研究
- 非小細胞肺癌44件の研究
- 肥満症31件の研究
- 転移性癌29件の研究
- 過体重27件の研究
- アルツハイマー病25件の研究
- 2型糖尿病24件の研究
- がん（全種類）24件の研究
- 乳がん23件の研究
- 卵巣がん22件の研究
- 潰瘍性大腸炎22件の研究
- 肺がん21件の研究
- 大腸癌19件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。